Abstract: There is provided insect models that are aimed to reflect vertebrate blood-brain barrier (BBB) penetration. Investigation of BBB penetration is extremely important in drug discovery; successful CNS drugs have to cross the BBB, while BBB penetration may cause unwanted side effects for peripheral acting drugs. Specifically, the present invention relates to the use of insects in screening for substances with a biological effect on the brain or central nervous system and/or effect on a disease or disorder of the brain or central nervous system. It further relates to use of such insects in screening for substances that have a desired biological activity and which do not cross the blood brain barrier.
Abstract: There is provided insect screening models to determine gastrointestinal absorption of different chemical compounds in vertebrates, and in particular humans, in order to improve the compound screening procedures/processes in the early drug discovery process. This offers many advantages relative to prior technologies since insect models are more reliable tools for the decision-making process than the existing in vitro models, and will speed up the drug screening process and reduce the late phase attrition rate. Moreover, it will reduce the number of mammals sacrificed during the drug discovery phase.
Type:
Grant
Filed:
August 10, 2010
Date of Patent:
November 3, 2015
Assignee:
Entomopharm ApS
Inventors:
Peter Aadal Nielsen, Gunnar Andersson, Olga Andersson
Abstract: There is provided an ex-vivo insect screening model to accurately determine blood-brain barrier penetration of different chemical compounds in order to improve the compound screening procedures/processes in the early drug discovery process. This object offers many advantages relative to prior technologies since insect models are more reliable tools for the decision-making process than the existing in vitro models, and will speed up the drug screening process and reduce the late phase attrition rate. Moreover, it will reduce the number of mammals sacrificed during the drug discovery phase.
Type:
Grant
Filed:
August 10, 2010
Date of Patent:
August 4, 2015
Assignee:
ENTOMOPHARM APS
Inventors:
Peter Aadal Nielsen, Gunnar Andersson, Olga Andersson
Abstract: There is provided an ex-vivo insect screening model to determine blood-brain barrier penetration of different chemical compounds. The method comprises the steps: • Optionally anesthetizing the insect • Fixing the head of the insect • Dissecting out the brain of the insect head thereby removing the brain from its cuticle • Optinally removing the neural lamella of the brain • Treating the brain with a solution of the chemical compound • Washing anf homogenising or ultra sound disintegrating the brain • Determining the concentration of the chemical compound in the homogenised brain material and • Calculating the penetration of the chemical compound through the blood-brain barrier The concentration of the chemical compound is determined by LC/MS and the chemical compound can be a CNS drug.
Type:
Application
Filed:
December 12, 2012
Publication date:
November 20, 2014
Applicant:
ENTOMOPHARM ApS
Inventors:
Peter Aadal Nielsen, Gunnar Andersson, Olga Andersson
Abstract: There is provided an ex-vivo insect screening model to accurately determine blood-brain barrier penetration of different chemical compounds in order to improve the compound screening procedures/processes in the early drug discovery process. This object offers many advantages relative to prior technologies since insect models are more reliable tools for the decision-making process than the existing in vitro models, and will speed up the drug screening process and reduce the late phase attrition rate. Moreover, it will reduce the number of mammals sacrificed during the drug discovery phase.
Type:
Application
Filed:
August 10, 2010
Publication date:
May 17, 2012
Applicant:
Entomopharm ApS
Inventors:
Peter Aadal, Gunnar Andersson, Olga Andersson
Abstract: There is provided insect screening models to determine gastrointestinal absorption of different chemical compounds in vertebrates, and in particular humans, in order to improve the compound screening procedures/processes in the early drug discovery process. This offers many advantages relative to prior technologies since insect models are more reliable tools for the decision-making process than the existing in vitro models, and will speed up the drug screening process and reduce the late phase attrition rate. Moreover, it will reduce the number of mammals sacrificed during the drug discovery phase.
Type:
Application
Filed:
August 10, 2010
Publication date:
May 17, 2012
Applicant:
Entomopharm ApS
Inventors:
Peter Aadal Nielsen, Gunnar Andersson, Olga Andersson
Abstract: There is provided a new methodology for initial assessment of compound PK. The invention is generally particular useful for efficient screening of and assessment of PK profiles of newly synthesized compounds in the early phase of drug discovery.
Type:
Application
Filed:
August 10, 2010
Publication date:
May 17, 2012
Applicant:
Entomopharm ApS
Inventors:
Peter Aadal Nielsen, Gunnar Andersson, Olga Andersson